FEMTELLE™ uPA/PAI-1 ELISA REF: 899

产品价格: < 面议
产品型号:
 牌:Shanghai Bioleaf Biotech Co Ltd
公司名称:上海拜力生物科技有限公司
  地:上海闵行
发布时间:2019-02-01
浏览次数:
更多
立即询价 在线咨询

产品简介

FEMTELLE™ uPA/PAI-1 ELISA REF: 899

产品详细信息

FEMTELLE™ uPA/PAI-1 ELISA REF: 899

Cancer Prognosis

FEMTELLE® is intended for the quantitative measurement of human Urokinase-type Plasminogen Activator (uPA) and human Plasminogen Activator Inhibitor Type-1 (PAI-1) in detergent extracts of breast tumor tissue. uPA and PAI-1 are clinically validated independent prognostic markers in breast cancer and have reached the highest Level of Evidence (LoE-1) according to the “Tumor Marker Utility System”.

FEMTELLE™ uPA/PAI-1 ELISA REF: 899

CE Marked

Prospective, randomized multi-center clinical trials as well as retrospective meta-analyzes have shown that measurement of both uPA and PAI-1 levels in extracts of breast cancer tumor tissue can help to assess the risk of disease recurrence. FEMTELLE results are useful for the following indications:
1. Prognosis for breast cancer patients who are either at low or high risk for disease recurrence following surgery. A low level of both uPA and PAI-1, below the established cutoff value of 3 ng uPA/mg of total protein and 14 ng of PAI- 1/ mg total protein, places the patient in the low risk category for disease recurrence. A high level of uPA and/or PAI-1, above the respective cut-off values, correlate with a significantly shortened Disease Free Survival (DFS) and reduced Overall Survival (OS) as compared to patients with tumor tissue containing low levels.
2. Prediction: It has been proposed that uPA and PAI-1 levels may be used to predict patient response to adjuvant chemotherapy. Clinical trials suggest that breast cancer patients with low uPA and PAI-1 are unlikely to benefit from adjuvant chemotherapy, whereas those patients with high uPA and PAI-1 levels are more likely to benefit from adjuvant chemotherapy.

Results from FEMTELLE should be used in conjunction with information available from clinical and other diagnostic procedures in the management of breast cancer disease

REAGENTS  
96 Anti-human PAI-1 IgG coated microwells
96 Anti-human uPA IgG coated microwells
6 Vials of PAI-1 Standards, 0-10 ng/mL, lyophilized
6 Vials of uPA Standards, 0-1.0 ng/mL, lyophilized
2 Vials of Detection Antibody, biotinylated anti-human PAI-1, lyophilized
2 Vials of Detection Antibody, biotinylated anti-human uPA, lyophilized
1 Vial of PAI-1 Enzyme Conjugate, Streptavidin-Horseradish Peroxidase, 60 μL
1 Vial of uPA Enzyme Conjugate, Streptavidin-Horseradish Peroxidase, 60 μL
2 Vials of Enzyme Conjugate Diluent, 20 mL, lyophilized
2 Vials of Substrate, TMB, 11 mL
2 Vials of Detergent, 25% Triton X-100, 12 mL
2 Packets of TBS Buffer, pH 9.6, powder
4 Packets of PBS Buffer, pH 7.4, powder
SPECIFICATIONS  
SAMPLES Detergent extracts of tumor tissue
SAMPLE PREPARATION 1:20 dilution in sample buffer
SAMPLE VOLUME 100 μL of diluted sample
TOTAL ASSAY TIME 2½ days, including detergent extraction
STANDARD RANGE PAI-1 0 – 10 ng/mL
LOWER LIMIT OF DETECTION, PAI-1 0.125 ng/mL
PRECISION, PAI-1 Intra-assay CV = 6.7%
Inter-assay CV = 4.7%
STANDARD RANGE, UPA 0 – 1.0 ng/mL
LOWER LIMIT OF DETECTION, UPA 0.025 ng/mL
PRECISION Intra-assay CV < 4.7%
Inter-assay CV < 3.9%
NUMBER OF TESTS 96



在线询价

您好,欢迎询价!我们将会尽快与您联系,谢谢!
  • *产品名称:
  • 采购数量:
  • 询价有效期:
  • *详细说明:
  •   100
  • *联系人:
  • *联系电话:
  • 附件: 附件支持RAR,JPG,PNG格式,大小在2M范围
验证码: 点击换一张
 
   温馨提示:为规避购买风险,建议您在购买前务必确认供应商资质与产品质量。

   免责申明:以上内容为注册会员自行发布,若信息的真实性、合法性存在争议,平台将会监督协助处理,欢迎举报
1